Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
Continued to Advance Monotherapy Dose Escalation Stage of Ongoing Phase 1/2 MYCHELANGELO™ I Study; Preliminary Data Anticipated in 2023Announced Clinical Supply Agreement with Roche to Evaluate... | May 4, 2023
Source: marketscreener.com